Tag Archives: Allerject

News: Sanofi to Return Allerject® Rights to kaléo

Sanofi Canada has issued a press release announcing that the License and Development Agreement between Sanofi and kaléo, formerly Intelliject Inc., the developer of Auvi-Q® and Allerject® (epinephrine injection, USP)  will terminate later this year. To see the full release, click here where you will also find contact information for the company. Special Note: Allerject®…  Read More

Mise à jour de Sanofi Canada sur le rappel volontaire d’Allerject®

POUR DIFFUSION IMMÉDIATE Laval (Québec) – le 2 décembre 2015 –  À la suite du rappel volontaire effectué par Sanofi-aventis Canada Inc. (Sanofi Canada), le 28 octobre 2015, de tous les lots d’auto-injecteurs d’épinéphrine Allerject® de 0,15 mg/0,15 mL et de 0,30 mg/0,3 mL, et étant donné la récente annonce confirmant que l’inventaire des autres auto-injecteurs d’épinéphrine est maintenant suffisant…  Read More

Update by Sanofi Canada on Nationwide Voluntary Recall of Allerject®

FOR IMMEDIATE RELEASE Laval, Quebec – December 2, 2015 – Following the October 28, 2015 voluntary recall by Sanofi-aventis Canada Inc. (Sanofi Canada) of all lots of Allerject® epinephrine auto-injectors of both the 0.15mg/0.15mL and 0.30mg/0.3mL strengths, and given the recent announcement that stock of alternative epinephrine auto-injectors is now sufficient to replace all Allerject®…  Read More

National voluntary recall of Allerject® products

Sanofi-aventis Canada Inc. has issued a voluntary recall of all Allerject® products, including both the 0.15 mg/0.15 mL and 0.3 mg/0.3mL strengths for hospitals, retailers and consumers. Please tweet, post and share this information with friends, family, school and anyone else who may need to know. Full text of the Sanofi recall Recall information from…  Read More